Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IMRA advanced for three days, in of 129 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day RSI Indicator for IMRA moved out of overbought territory on September 23, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 similar instances where the indicator moved out of overbought territory. In of the 16 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on September 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IMRA as a result. In of 49 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
IMRA moved below its 50-day moving average on September 23, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IMRA broke above its upper Bollinger Band on September 18, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMRA entered a downward trend on September 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
a company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies
Category Unknown